Investor Information: 2011 Press Releases

Receive E-mail AlertsE-mail Alerts
Keyword Search
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009
12/16/11Daily Glow Names NEOVA® DNA Damage Control™ SILC Sheer SPF 45
NEOVA® Takes Top Honor in “Sunscreen with Superpowers” Category Mongomeryville, PA (December 16. 2011) – Today Daily Glow has announced the winners for their inaugural awards program to acknowledge the top beauty products that are bringing innovation to the forefront of the industry. NEOVA® is pleased to announce that DNA Damage Control™ SILC SHEER SPF 45 earned a Daily Glow Award in the Biggest Breakthrough “Sunscreen with Superpowers” category. Damage Control SILC SHEER SPF 45 by NEOV... 
Printer Friendly Version
12/13/11PhotoMedex and Radiancy Complete Merger
MONTGOMERYVILLE, Pa. & ORANGEBURG, N.Y.--(BUSINESS WIRE)--Dec. 13, 2011-- PhotoMedex, Inc. (Nasdaq: PHMD), (“PhotoMedex”) a leader in the development of proprietary excimer laser, LED light systems and skin care products for dermatological applications, and Radiancy, Inc., (“Radiancy”) a leading developer and manufacturer of home-use and professional aesthetic and dermatological devices, today announced that their respective stockholders have voted to approve the adoption of the Amended and Rest... 
Printer Friendly Version
11/29/11PhotoMedex Helps Psoriasis Patients Ease Winter Skin Care Woes
MONTGOMERYVILLE, Pa., Nov. 29, 2011 /PRNewswire/ -- Winter brings a whole set of skin problems for many people, however, these problems are even worse for the 7.5 million Americans who suffer from psoriasis. Cold weather, dry indoor heat, lack of ultraviolet rays from sunlight and other environmental factors rob the skin of the moisture it needs, causing psoriasis symptoms to flare up. Additionally, winter colds weaken the immune system, making it harder for the body to resist p... 
Printer Friendly Version
11/23/11PhotoMedex Announces Effectiveness of Form S-4
Registration Statement for the proposed Merger with Radiancy, Inc. MONTGOMERYVILLE, Pa.--(BUSINESS WIRE)--Nov. 23, 2011-- PhotoMedex, Inc. (Nasdaq: PHMD), (“PhotoMedex”) a leader in the development of proprietary excimer laser, LED light systems and skin care products for dermatological applications, today announced that the Securities and Exchange Commission (SEC) has declared PhotoMedex’ Registration Statement on Form S-4 relating to the previously announced proposed merger between PhotoMede... 
Printer Friendly Version
10/24/11PhotoMedex Increases Access to Care for Children in Recognition of World Psoriasis Day, Oct. 29
PhotoMedex covers co-pays for XTRAC excimer laser treatments for children MONTGOMERYVILLE, Pa., Oct. 24, 2011 /PRNewswire via COMTEX/ --PhotoMedex, Inc. (NASDAQ: PHMD), an innovator of medical devices, including the XTRAC® excimer laser (, is offering a special co-pay reimbursement program to increase access to XTRAC psoriasis treatments for children, an underserved population of psoriasis patients. The offer is being presented in recognition of World Psoriasis Day on ... 
Printer Friendly Version
10/17/11XTRAC Excimer Laser Provides Relief for Psoriasis Sufferers' Fall Flare-Ups
MONTGOMERYVILLE, Pa., Oct. 17, 2011 /PRNewswire via COMTEX/ --For the 7.5 million Americans suffering from psoriasis, the fall season brings more than just shorter days, less access to sunlight and colder temperatures. The season also brings worsening psoriasis symptoms. With XTRAC® Excimer Laser ( treatments, psoriasis patients can receive relief from fall flare-ups. Although every season provides its own unique set of challenges for psoriasis patients, the fall and cold... 
Printer Friendly Version
08/04/11PhotoMedex Covers XTRAC Laser Treatment Co-Pay for Children with Psoriasis
Rebate offer increases access to care for children in honor of National Psoriasis Awareness Month MONTGOMERYVILLE, Pa., Aug. 4, 2011 /PRNewswire via COMTEX/ --PhotoMedex, Inc. (NASDAQ:PHMD), an innovator of medical devices, today launches a co-pay reimbursement offer* to assist the families of children who suffer from psoriasis. In honor of the National Psoriasis Awareness Month in August (and continuing through November), children, who may not have been able to afford treatments, will hav... 
Printer Friendly Version
07/18/11PhotoMedex's 'Itching to Win' Contest Offers Free Phototherapy Treatments With the XTRAC Laser to Deserving Psoriasis Patients Nationwide
MONTGOMERYVILLE, Pa., July 18, 2011 /PRNewswire via COMTEX/ --In honor of National Psoriasis Awareness Month in August, PhotoMedex, Inc. (NASDAQ: PHMD), an innovator of medical devices, today has launched the "Itching to Win" contest, an opportunity for six deserving psoriasis patients to win a full series of treatments with the XTRAC excimer laser. The XTRAC laser is the only clinically proven, FDA-cleared dermatology excimer laser with independent safety and quality certifications. It pro... 
Printer Friendly Version
07/05/11PhotoMedex Announces Definitive Merger Agreement with Radiancy
Combined company foresees significant new sales opportunities in global consumer and professional skin-care markets, and has pro forma revenues of $132 million for the 12 months ended March 31, 2011 PhotoMedex shareholders to own approximately 25% of the company on a fully converted basis Radiancy to provide cash for PhotoMedex to repurchase convertible notes and accrued interest at closing - balance of $22.4 million at June 30, 2011 Conference call to be held July 11, 2011 at 4:00 p.m. E... 
Printer Friendly Version
06/08/11XTRAC Laser Provides New Hope for Children with Psoriasis
Treatment helps ease physical and emotional pain caused by psoriasis MONTGOMERYVILLE, Pa., June 8, 2011 /PRNewswire via COMTEX/ --About 20,000 children in the United States under the age of 10 are diagnosed with psoriasis every year. For many, the disease goes beyond painful red, dry patches of scaly, thickened skin; the emotional side-effects are equally life altering--with nearly 50 percent of children reporting that they have been bullied because of their disease. The XTRAC® Excimer Laser... 
Printer Friendly Version
05/18/11XTRAC Laser Treatment Offers Summer Time Relief to Psoriasis Sufferers Covered by Major Insurers
Psoriasis patients can prepare for fun in the summer sun MONTGOMERYVILLE, Pa., May 18, 2011 /PRNewswire via COMTEX/ --With XTRAC® Excimer Laser ( treatments, psoriasis patients can say goodbye to the red, dry patches of scaly, thickened skin they have been covering up all winter. Developed by PhotoMedex, Inc. (NASDAQ: PHMD), an innovator of medical devices, the XTRAC laser offers new hope to the 7.5 million Americans suffering from this embarrassing and socially isolating d... 
Printer Friendly Version
05/05/11NEOVA® Launches DNA Repair-Based Treatment Sunscreens
DNA Repair Enzymes Increase UV Protection by 300% in One Hour MONTGOMERYVILLE, Pa., May 5, 2011 /PRNewswire via COMTEX/ --PhotoMedex, Inc. (Nasdaq: PHMD) a leading supplier of advanced, clinical skincare and medical laser products, today introduced DNA Damage Control, the breakthrough treatment sunscreens that feature advanced photoprotection with DNA repair technology. Formulated by and marketed under the company's NEOVA® brand, the DNA Damage Control sunscreens offer an unrivaled repai... 
Printer Friendly Version
03/31/11PhotoMedex Reports 2010 Fourth Quarter and Full Year Results
MONTGOMERYVILLE, Pa., Mar 31, 2011 (BUSINESS WIRE) -- PhotoMedex, Inc. (NASDAQ GM: PHMD) today reported financial results for the three and 12 months ended December 31, 2010. Please note that all per-share figures reflect the February 3, 2010 1-for-6 reverse stock split. Financial highlights of the 2010 fourth quarter and year include: Revenues for the fourth quarter increased 27% to $10.5 million from the prior year. Revenues for the year increased 6.5% to $34.8 million from the prior y... 
Printer Friendly Version
03/29/11Clinical Trial Offers New Hope for Moderate to Severe Psoriasis Sufferers
Study using the XTRAC(R) Velocity 700 excimer laser shows signs of relief for psoriasis patients MONTGOMERYVILLE, Pa., March 29, 2011 /PRNewswire via COMTEX/ --PhotoMedex, Inc. (Nasdaq: PHMD) announced today the implications of the preliminary findings of a current clinical trial being performed by John Y.M. Koo, M.D., professor and vice chairman, department of dermatology, University of California, San Francisco. Dr. Koo's experimental treatment protocol could change the lives of millions of... 
Printer Friendly Version